[Market Focus] Ligachem Bio Rises 5% on Attractive Valuation Assessment

Ligachem Bio rose more than 5% in early trading, following assessments that the company holds strong valuation appeal even within the biotech sector.

According to the Korea Exchange on March 17, as of 9:12 a.m., Ligachem Bio was trading at 208,000 won, up 3.48% from the previous trading day. Earlier in the session, the stock reached as high as 212,000 won, marking a 5.47% increase from the previous day.

On this day, Korea Investment & Securities released a report describing Ligachem Bio as a "biotech company with attractive valuation."

Heeju Wi, a researcher at Korea Investment & Securities, explained, "The market capitalization of KOSDAQ-listed biotech companies is generally higher compared to their cumulative technology transfer amounts, but Ligachem Bio’s market capitalization is lower than its cumulative technology transfer amount of 9.6 trillion won." He analyzed, "Ligachem Bio is the only biotech company where such a gap between market capitalization and achievements is observed."

The researcher emphasized, "There are more momentum drivers expected for this year compared to other companies." He added, "More than three clinical trial results, including LCB14, LCB71, and LCB41A, are expected to be announced by mid-year, and technology transfer negotiations that have been underway since last year could yield tangible results in 2026."

In particular, he pointed out that for LCB84, an antibody-drug conjugate (ADC) candidate targeting solid tumors that was licensed out to Janssen in October 2023, there is a high possibility that Janssen will exercise its exclusive development option.

This content was produced with the assistance of AI translation services.